Protalix BioTherapeutics, Inc. (NYSE: PLX), a biopharmaceutical company specializing in the development, production, and commercialization of recombinant therapeutic proteins, recently disclosed its ...
Amgen today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C., ...
"We are pleased to report that all eight cohorts of our phase I first-in-human study of PRX-115, our recombinant uricase candidate being developed for the treatment of uncontrolled gout, are now ...
Gout causes sudden flares of joint pain, which often arise during the nighttime, and in the big toe, though it may affect other joints including the ankles | Genetics And Genomics ...
A new study has found that SGLT-2 inhibitor drugs for type 2 diabetes may also reduce the risk of kidney stones and gout. These painful conditions are ...